SCHEMBL3240341

SCHEMBL3240341

Fc1ccc(NCc2cc[c]c(Cl)c2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
MAPT P10636 5/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
ALDH1A1 P00352 2/20 0.41
THRB P10828 1/20 0.41
PKM P14618 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 1/20 0.41
BLM P54132 1/20 0.41
CASP6 P55212 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
GAA P10253 3/20 0.40
HDAC4 P56524 1/20 0.39
MEF2D Q14814 1/20 0.39
KCNH3 Q9ULD8 3/20 0.39
PPARA Q07869 3/20 0.38
KDM4E B2RXH2 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3246772 0.87 NPC1 (0.46) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL3242481 0.83 MAPT (0.43) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL3248749 0.83 HPGD (0.51) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL3246912 0.81 MAPT (0.45) MAPTMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL14672469 0.81 AURKA (0.43) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL3249812 0.77 MEN1 (0.45) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL18768917 0.75 CYP1A2 (0.59) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL6448992 0.73 CYP1A2 (0.59) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL6419238 0.72 LMNA (0.61) LMNAMAPTMEN1KMT2AL3MBTL1
SCHEMBL10055033 0.72 LMNA (0.61) LMNAMAPTMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP claimed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO claimed
EP-2185149-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. Lundbeck A/S (DK) 2010-05-19 EP disclosed
WO-2009015667-A1 USE OF KNCQ POTASSIUM CHANNEL OPENERS FOR REDUCING SYMPTOMS OF OR TREATING DISORDERS OR CONDITIONS WHEREIN THE DOPAMINERGIC SYSTEM IS DISRUPTED H. LUNDBECK A/S (DK) 2009-02-05 WO disclosed